Detalles de la búsqueda
1.
Predictors of unsustained measurable residual disease negativity in patients with multiple myeloma.
Blood
; 143(7): 592-596, 2024 Feb 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-38048557
2.
Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: a multicenter, retrospective, real-world experience with 200 cases outside of controlled clinical trials.
Haematologica
; 109(1): 245-255, 2024 01 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37439329
3.
Lenalidomide-based triplet regimens in first relapsed multiple myeloma patients: real-world evidence from a propensity score matched analysis.
Haematologica
; 108(3): 833-842, 2023 03 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36200419
4.
A prospective, multicenter study on hematopoietic stem-cell mobilization with cyclophosphamide plus granulocyte colony-stimulating factor and 'on-demand' plerixafor in multiple myeloma patients treated with novel agents.
Haematologica
; 2023 Nov 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-37981892
5.
Doxorubicin-Mediated miR-433 Expression on Exosomes Promotes Bystander Senescence in Multiple Myeloma Cells in a DDR-Independent Manner.
Int J Mol Sci
; 24(7)2023 Apr 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-37047835
6.
Cross-Dressing of Multiple Myeloma Cells Mediated by Extracellular Vesicles Conveying MIC and ULBP Ligands Promotes NK Cell Killing.
Int J Mol Sci
; 24(11)2023 May 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-37298418
7.
Phytochemical Analysis and In Vitro Antileukemic Activity of Alkaloid-Enriched Extracts from Vinca sardoa (Stearn) Pignatti.
Molecules
; 28(15)2023 Jul 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-37570609
8.
Thrombosis in multiple myeloma: risk stratification, antithrombotic prophylaxis, and management of acute events. A consensus-based position paper from an ad hoc expert panel.
Haematologica
; 107(11): 2536-2547, 2022 11 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35861017
9.
Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial.
Lancet Oncol
; 22(12): 1705-1720, 2021 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-34774221
10.
Carfilzomib, cyclophosphamide and dexamethasone for newly diagnosed, high-risk myeloma patients not eligible for transplant: a pooled analysis of two studies.
Haematologica
; 106(4): 1079-1085, 2021 04 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32107329
11.
Venous thromboembolism prophylaxis in patients with multiple myeloma: where are we and where are we going?
J Thromb Thrombolysis
; 52(2): 584-589, 2021 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-33417149
12.
Lenalidomide-based induction and maintenance in elderly newly diagnosed multiple myeloma patients: updated results of the EMN01 randomized trial.
Haematologica
; 105(7): 1937-1947, 2020 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-31582542
13.
Activation of liver X receptor up-regulates the expression of the NKG2D ligands MICA and MICB in multiple myeloma through different molecular mechanisms.
FASEB J
; 33(8): 9489-9504, 2019 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-31125275
14.
High rate of profound clonal and renal responses with daratumumab treatment in heavily pre-treated patients with light chain (AL) amyloidosis and high bone marrow plasma cell infiltrate.
Am J Hematol
; 95(8): 900-905, 2020 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-32282971
15.
Che-1-induced inhibition of mTOR pathway enables stress-induced autophagy.
EMBO J
; 34(9): 1214-30, 2015 May 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-25770584
16.
Once-weekly versus twice-weekly carfilzomib in patients with newly diagnosed multiple myeloma: a pooled analysis of two phase I/II studies.
Haematologica
; 104(8): 1640-1647, 2019 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-30733270
17.
Diagnostic framing of IgM monoclonal gammopathy: Focus on Waldenström macroglobulinemia.
Hematol Oncol
; 37(2): 117-128, 2019 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-30192023
18.
Is re-challenge still an option as salvage therapy in multiple myeloma? The case of REal-life BOrtezomib re-Use as secoND treatment for relapsed patients exposed frontline to bortezomib-based therapies (the REBOUND Study).
Ann Hematol
; 98(2): 361-367, 2019 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-30353388
19.
Cardiovascular adverse events in modern myeloma therapy - Incidence and risks. A review from the European Myeloma Network (EMN) and Italian Society of Arterial Hypertension (SIIA).
Haematologica
; 103(9): 1422-1432, 2018 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-30049825
20.
Cyclophosphamide's addition in relapsed/refractory multiple myeloma patients with biochemical progression during lenalidomide-dexamethasone treatment.
Eur J Haematol
; 2018 May 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-29719938